Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas

Table 1 Demographic and clinical characteristics of the 44 patients who completed the questionnaires (mean ± SD)

	n (%)
Sex
Males	18 (40.9)
Females	26 (59.1)
Age at interview (yr)	61.0 ± 9.8
Disease duration (yr)	5.8 ± 5.4
Body mass index (kg/m2)	25.9 ± 4.3
Marital status
Single/Widowed/Divorced	10 (22.7)
Married	34 (77.3)
Diploma
Elementary school	11 (25.0)
Middle school	18 (40.9)
High school	10 (22.7)
University degree	5 (11.4)
Job
Current workers	32 (72.7)
Managers	6
Employees	16
Industrial workers	3
Housewives	7
Retired	12 (27.3)
Alcohol habit
Alcohol drinkers	18 (40.9)
Current drinkers	14
Drinking duration (yr)	40.2 ± 12.5
Smoking habit
Smokers	20 (45.5)
Actual smokers	5
No. of cigarettes smoked per day	10.6 ± 5.9
Smoking duration (yr)	28.7 ± 13.3
Comorbidities	30 (68.2)
Non disease specific drugs	35 (79.5)
Previous surgery not due to neuroendocrine tumors	33 (77.0)
Surgery due to pancreatic neuroendocrine tumors	35 (79.5)
Pancreatic head resection	8
Distal pancreatectomy	20
Total pancreatectomy	2
Enucleation	5
Status of neuroendocrine tumors
Disease free	25 (56.8)
Lymph node involvement/liver metastases	19 (43.2)
Specific drugs and treatment
No drugs	30 (68.2)
Somatostatin analogues alone	9 (20.5)
Somatostatin analogues plus radiometabolic therapy	5 (11.4)
Pain in the month prior to complete the questionnaire	17 (38.6)
Dyspepsia	24 (54.5)
Diabetes	12 (27.3)

Data are reported as absolute and relative frequencies or mean ± SD.